Printer Friendly

IMMUNEX TO ACQUIRE EXCLUSIVE GM-CSF RIGHTS

 SEATTLE, March 29 /PRNewswire/ -- Immunex Corp. (NASDAQ: IMNX) announced today that the Federal Trade Commission (FTC) has voted not to oppose the company's reacquisition of exclusive U.S. marketing rights to GM-CSF from its development and co-marketing partner, Hoechst AG.
 Immunex and Hoechst's U.S. affiliate, Hoechst-Roussel Pharmaceuticals Inc., have been co-marketing GM-CSF in the United States under the respective brand names LEUKINE(R) and PROKINE(TM). Immunex manufactures the drug for both companies. In July 1992 Immunex and Hoechst, settling a contract dispute, agreed to transfer exclusive U.S. rights to the drug to Immunex in return for significantly increased royalties. Earlier today the FTC announced that it had voted to terminate its investigation and would not seek to block the transfer.
 In 1991 the U.S. Food and Drug Administration (FDA) approved the use of GM-CSF for the acceleration of marrow engraftment following autologous bone marrow transplantation to treat certain cancers, and to extend survival of patients whose bone marrow transplants have failed. Last week the European Community's Committee for Proprietary Medicinal Products recommended approval of GM-CSF for these same indications. Immunex expects to file a product license amendment with the FDA later this week for expanded use of the drug.
 Immunex is a biopharmaceutical company focused on the discovery, development, manufacture and marketing of products to treat cancer and autoimmune disease.
 -0- 3/29/93
 /CONTACT: Jason Rubin of Immunex, 206-587-0430/
 (IMNX)


CO: Immunex; Federal Trade Commission; Hoechst AG; Hoechst-Roussel
 Pharmaceuticals Inc. ST: Washington IN: MTC SU:


SW -- SE016 -- 0773 03/29/93 18:49 EST
COPYRIGHT 1993 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1993 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Mar 29, 1993
Words:259
Previous Article:MARINERS AND KING COUNTY ANNOUNCE NEW SPONSOR FOR KINGDOME SIGN
Next Article:GRANTS PASS AND NORTH BEND SIZZLERS TO CLOSE TEMPORARILY
Topics:


Related Articles
IMMUNEX COMPLETES LANDMARK YEAR; PRODUCT LAUNCH, NEW MANUFACTURING CENTER, CLINICAL PROGRAMS HIGHLIGHT 1991 ACHIEVEMENTS
IMMUNEX SUES HOECHST FOR BREACH OF CONTRACT, BUSINESS INTERFERENCE, UNFAIR COMPETITION; PROJECTS QUARTER LOSS DUE TO REDUCED GM-CSF SALES
BEHRINGWERKE, HOECHST-ROUSSEL COMMENCE ACTION AGAINST IMMUNEX
IMMUNEX, HOECHST SETTLE CONTRACT DISPUTE, REVISE GLOBAL COLLABORATION
IMMUNEX TO ACQUIRE EXCLUSIVE GM-CSF RIGHTS
IMMUNEX STATEMENT ON GROWTH FACTOR STUDIES IN AML
IMMUNEX, JOHNS HOPKINS UNIVERSITY CREATE RESEARCH COLLABORATION ON GM-CSF
IMMUNEX AND AMERICAN HOME PRODUCTS REVISE RESEARCH AGREEMENTS
Medical Market Embraces New Leukine Liquid
Immunex Licenses G-CSF Receptor Patent Rights to SmithKline Beecham

Terms of use | Copyright © 2017 Farlex, Inc. | Feedback | For webmasters